Cash Flow Statement

Acquisitions Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Growth Metrics

Others

Tonix Pharmaceuticals Holding (TNXP) Asset Writedowns and Impairment (2024 - 2025)

Tonix Pharmaceuticals Holding has reported Asset Writedowns and Impairment over the past 2 years, most recently at -$649000.0 for Q4 2025.

Quarterly results put Asset Writedowns and Impairment at -$649000.0 for Q4 2025, up 98.87% from a year ago — trailing twelve months through Dec 2025 was -$57.9 million (changed N/A YoY), and the annual figure for FY2025 was $669000.0, down 55.1%.
Asset Writedowns and Impairment for Q4 2025 was -$649000.0 at Tonix Pharmaceuticals Holding, down from -$100000.0 in the prior quarter.
Over the last five years, Asset Writedowns and Impairment for TNXP hit a ceiling of $59.0 million in Q2 2024 and a floor of -$57.5 million in Q4 2024.